TargED Biopharmaceuticals B.V.

• A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polys… Not authorised
  2022-500228-31-00 Phase II/III 1 country PARACETAMOL; PENTOSAN POLYSULFATE SODIUM; TETRACOSACTIDE
• TGD001 Treatment in Thrombotic Microangiopathies Pending
  2025-523802-34-00 Phase I/II 4 countries UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILL…
• A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have … Recruiting
  2025-521730-28-00 Phase II 5 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST GDNF FAMILY RECEPTOR ALPHA-LIKE
• Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting
  2025-522455-26-00 Phase I/II 3 countries UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILL…
• A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer Recruiting
  2024-510691-20-00 Phase II 3 countries TOVORAFENIB
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended
  2024-510742-13-00 Phase III 16 countries CARBOPLATIN; TOVORAFENIB; VINBLASTINE SULFATE; VINCRISTINE SULFATE
• TGD001 SAD study in healthy volunteers Ended
  2024-514931-63-00 Phase I 1 country
• A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polys… Ended
  2022-500228-31-01 Phase II/III 3 countries PARACETAMOL; PENTOSAN POLYSULFATE SODIUM; TETRACOSACTIDE
• A Phase 1/2 Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors Ended
  2022-503060-33-00 Phase II 3 countries NGM707; PEMBROLIZUMAB

Showing 1–9 of 9 trials